Our data (Figure 4C) shows that small molecule CXCR2 antagonist AZD5069 not only effected a significant decrease in the influx of TANs toward the BrM tumor, but also a reduction in the overall density of the NETs produced by the infiltrating neutrophils. The gene discussed is CXCR2; the disease is neoplasm.